News · Longevity & Aging
Where more babies got the RSV antibody shot, fewer came to emergency rooms, across 12 European countries
Nirsevimab protects infants against the virus behind most bronchiolitis. Its real-world effect varied widely across Europe, and one number tracked that variation closely: how many babies got it.
- An observational study of 107,088 bronchiolitis cases at 27 children's emergency departments in 12 European countries.
- It compared regions that gave infants nirsevimab, a protective antibody against RSV, with regions that did not.
- Drops in emergency visits ranged from almost none to 61%, depending on the region and the baby's age.
- Higher coverage tracked closely with bigger drops; regions without the program saw no change.
- This compares whole regions, not individual babies, so other local differences may play a part.
Every winter, children’s emergency rooms across Europe fill with babies who are struggling to breathe. The usual cause is bronchiolitis, an infection of the smallest airways. The usual culprit is a virus called RSV. In 2023 a new tool arrived: nirsevimab, one shot of antibody that guards a baby through the season. Trials had shown it worked. What nobody knew was how much it would help in the real world.
A study in PLOS Medicine looked at 107,088 bronchiolitis cases across 12 European countries. The answer depended, more than anything, on how many babies actually got the shot.
What RSV does to babies
MedlinePlus describes respiratory syncytial virus, or RSV, as a common respiratory virus, and notes that nearly all children become infected with RSV by age 2. For most it is a cold. The danger lies elsewhere: it can cause serious lung infections, especially in infants, older adults, and people with serious medical problems.
In young babies that serious infection is bronchiolitis. The smallest airways swell and fill with mucus. Feeding gets hard, and some babies need oxygen or help to breathe. Because it is so common, even a small drop in cases takes real pressure off hospitals each winter.
How the nirsevimab study was set up
The researchers used routinely collected data from 27 pediatric emergency departments across 12 European countries, covering January 2018 to March 2024, so they could compare several normal seasons with the first season the antibody was offered.
Regions that introduced nirsevimab were compared with regions that did not, and the study looked separately at babies under 3 months and those aged 3 to 12 months. A clever control helped: urinary tract infections served as a control outcome, a common reason for emergency visits that the antibody should not touch.
What happened to bronchiolitis visits
The effect was anything but uniform. Reductions varied widely across regions and age-groups, from +0.6% to -61.0%. Some regions saw emergency visits for bronchiolitis fall by more than half; others saw essentially nothing.
What explained the difference was coverage, the share of eligible babies who received the injection. Coverage strongly correlated with bronchiolitis reduction across age-groups and regions, and the correlation was strikingly tight. Meanwhile, bronchiolitis trends in control countries remained stable, as did urinary tract infections, which makes it less likely that something else was driving the change.
Why nirsevimab coverage, not just the drug, matters
The antibody works; that was already established. This study shows that a proven product only delivers its benefit to the babies it reaches. The authors put it in one line: nirsevimab benefits depend not only on its intrinsic efficacy, but also on how effectively it is delivered.
That shifts attention to the plain work of getting the shot to babies. Is the shot offered in the maternity ward before a baby goes home? Are babies born before the season called back? Do parents hear about it in time? Those choices vary between countries, and they seem to decide how many emergency visits are avoided. The authors suggest implementation choices across Europe likely drove the differences in coverage, which is a practical lesson for any health system planning its next season.
What a region-level bronchiolitis study cannot show
This is an ecological study, one that compares whole regions rather than following individual babies. The authors state plainly that causality cannot be inferred and unmeasured regional differences may have contributed to the variability.
Cases were found from hospital codes, not checked by hand. Coverage figures were regional totals that may not match the babies each hospital serves. The study covers one season, and newer questions, such as whether the virus finds ways around the antibody, need longer watching.
What this changes for parents and health services
For parents, the finding is simple: where the antibody is offered, it appears to keep babies out of emergency departments, and the more families who take it up, the larger the benefit for everyone’s hospital.
For health services, it is a reminder that buying a product is only half the job. Regions that reached most babies saw the biggest falls in winter emergencies, and the difference between a drop of 61% and none at all came down largely to how well the program was run.
People also ask
What did the study find?
Reductions in bronchiolitis cases varied widely across regions and age groups, from +0.6% to -61.0%. Coverage strongly correlated with bronchiolitis reduction across age groups and regions (correlation -0.86). Bronchiolitis trends in control countries remained stable, as did urinary tract infections, which served as a control outcome.
What is nirsevimab?
A long-acting antibody given as a single injection that gives a baby ready-made protection against RSV for a season. It is not a vaccine in the usual sense, because the baby's own immune system does not have to learn anything; the protection is supplied directly.
What is bronchiolitis?
An infection of the smallest airways in a baby's lungs, most often caused by RSV. It causes coughing, wheezing and difficulty breathing and is a leading reason young babies are admitted to hospital in winter.
Why use urinary tract infections as a comparison?
They are a common reason babies visit emergency departments that nirsevimab should not affect. Because they stayed stable, it is less likely that the drop in bronchiolitis came from a general change in how often families sought care.
Does this prove the antibody works?
Its effectiveness was already shown in trials. This study asks a different question: how much of that benefit a region actually gets, and the answer depends heavily on how many babies are reached.
Should my baby get it?
Recommendations vary by country and season, and depend on your baby's age and circumstances. Ask your pediatrician or local health service what is offered. This is general information rather than medical advice.